The Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma

Launched by CHINESE PLA GENERAL HOSPITAL · Mar 16, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring two treatment options for patients with low-risk papillary thyroid cancer, which is a common type of thyroid cancer. The researchers want to compare the results of a procedure called ultrasound-guided thermal ablation, where heat is used to destroy cancer cells, with traditional thyroid surgery. They are also working on an artificial intelligence tool that can help predict how well the thermal ablation treatment will work for patients.

To participate in this trial, individuals should be between 18 and 80 years old and have been diagnosed with papillary thyroid cancer through specific tests. The cancer must be small, measuring no more than 2 centimeters, and there should be no signs that it has spread beyond the thyroid. Participants can expect to be followed for at least 12 months to monitor their health and the effectiveness of the treatments. This study is currently recruiting participants of all genders, and it's important for anyone considering joining to discuss their eligibility with their healthcare provider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. patients age between 18 and 80 year old, both sex
• • 2. papillary thyroid carcinoma confirmed by core-needle biopsy or fine-needle aspiration
• • 3. the largest diameter ≤2.0 cm
• • 4. no clinical or imaging evidences of extrathyroidal extension, lymph node metastasis and distant metastasis on ultrasound, nech and chest CT
• • 5. follow-up period ≥12 months,
• Exclusion Criteria:
• • 1. patients with convincing evidence of aggressive papillary thyroid carcinoma or other type of thyroid cancer by biopsy
• • 2. history of neck radiation
• • 3. history of thyroid surgery
• • 4. coagulation disorder
• • 5. serious heart, respiratory, liver, or renal failure
• • 6. dysfunction of the vocal cord on the opposite side